You indicated that you are taking medication(s) for your (identify health concern, such as “high blood pressure”). Individuals have identified several issues regarding their medication-taking behavior, and we are interested in your experiences. There is no right or wrong answer. Please answer each question based on your personal experience with your [health concern] medication.
1. Do you sometimes forget to take your medication?
2. People sometimes miss taking their medications for reasons other than forgetting. Thinking over the past two weeks, were there any days when you did not take your medication?
3. Have you ever cut back or stopped taking your medication without telling your doctor, because you felt worse when you took it?
4. When you travel or leave home, do you sometimes forget to bring your medication?
5. Did you take your medication yesterday?
6. When you feel like your symptoms are under control, do you sometimes stop taking your medication?
7. Taking medication every day is a real inconvenience for some people. Do you ever feel hassled about sticking to your treatment plan?
8. How often do you have difficulty remembering to take all your medications?
Data Submission and Platform Integration
As part of the MMAS Researcher Program, participants are encouraged to complete and return the provided MMAS App Scoring Excel Worksheet in its entirety. This structured worksheet supports consistency in administration, accuracy in scoring, and alignment across research projects, particularly when used in multi-site or comparative analyses.
For those who elect to participate, completed worksheets may be securely transmitted to Adherence for potential integration into the ATLAS behavioral intelligence platform: our advanced geospatial and analytics system. ATLAS is designed to model population-level adherence trends in real time, enabling researchers to explore behavioral patterns, generate hypotheses, and inform the development of targeted interventions.
Participation in ATLAS is entirely optional and remains at the discretion of the research team, particularly in cases where local data governance, ethics committee guidance, or regional regulations restrict external sharing—even of de-identified data. Where participation is possible, contributions are welcomed and highly valued.
The MMAS worksheet itself does not contain any fields for personally identifiable information, and all submitted data must remain fully de-identified in accordance with HIPAA, GDPR, and other relevant data protection standards. Data housed within ATLAS is stored in a secure, encrypted environment and used only under strict governance protocols to protect both the research and the researchers.
Those who contribute data to ATLAS become part of a broader scientific community exploring the behavioral drivers of adherence globally. Participation may open pathways for future academic collaboration, multi-center studies, or joint dissemination efforts. In select cases, it may also support innovation initiatives in digital health or real-world outcomes modeling.
We view every dataset not only as a contribution to adherence science, but as a foundation for building more personalized, scalable, and behaviorally grounded approaches to care.
If you have any questions about completing the worksheet, data use policies, or your options for participating in ATLAS, please feel free to reach out to our research support team. We’re here to support your work.
END-USER LICENSE AGREEMENT (EULA)
MMAS® – MORISKY MEDICATION ADHERENCE SCALE
Effective Date: 2025
This End-User License Agreement is a binding legal document between the end user (“Licensee”) and MMAR, LLC dba ADHERENCE (“Licensor”), the sole authorized owner of the Morisky Medication Adherence Scale (MMAS®), including all associated versions, translations, scoring algorithms, data collection instruments, and behavioral constructs derived from or based on the original work of Dr. Donald E. Morisky.
By accessing, using, reproducing, or integrating the MMAS in any form of academic, research, or health-related project, the Licensee affirms agreement to the terms and conditions set forth herein.
The Licensor grants to the Licensee a limited, non-transferable, non-exclusive license to use the MMAS solely for academic, scholarly, or clinical research purposes. This license does not confer any rights to reproduce, modify, publish, sublicense, adapt, redistribute, or commercially deploy the MMAS in any format, whether physical, digital, or derivative, without express written consent from the Licensor.
All Licensees must complete the Ξxpert Introductory Training prior to use. This training provides the minimum required foundation for responsible use, including interpretation, phrasing protocols, and consistent administration. The MMAS is a proprietary behavioral instrument and must be applied in its validated structure, with no substitutions, alterations, or unapproved translations. Requests to validate new linguistic or cultural versions, or to use the revised MMAS-8R, must be submitted in writing and may be permitted with oversight.
The Licensee acknowledges and agrees that the MMAS, including but not limited to MMAS-4™, MMAS-8™, MMAS-8R™, and all translations, item structures, and scoring systems, is the exclusive intellectual property of the Licensor and is protected by U.S. and international laws. The MMAS trademark and associated names; including Morisky Medication Adherence Scale™, MMAS™, ATLAS Platform™, and Ξxpert™, may only be used in connection with properly licensed research under this agreement. Use of any version of the MMAS under a different name, or the rebranding or co-authorship of the scale or its derivatives, is strictly prohibited and will be treated as a breach of license.
The MMAS scoring system is considered a trade secret and may not be disclosed, reverse-engineered, embedded in digital applications, published in full, or reproduced in any public forum, including but not limited to appendices, online supplements, open-access platforms, or grant applications, without explicit written permission. Approved descriptive language may be used in publications and is available upon request. The scoring structure is to be accessed and applied only through official materials provided by the Licensor, and stored in a secure, non-public manner.
The standard MMAS Scoring Excel Worksheet is provided as a core tool to assist with structured data capture. Submission of this worksheet to Adherence, while not mandatory, is encouraged. Where permissible, de-identified datasets may be optionally integrated into the ATLAS behavioral intelligence platform. ATLAS is a secure, encrypted system designed to model aggregate behavioral adherence trends across populations. Institutions that contribute data do so without transferring ownership, and remain eligible to access selected outputs for academic purposes. Participation in ATLAS is entirely voluntary and is not a condition of this license.
All research publications, presentations, or public uses of MMAS-derived data must include proper attribution as follows:
MMAS® 2006. Used with permission. www.adherence.cc.
Licensees are also asked to provide a copy of any resulting publication, preprint, or final article for documentation and quality control.
Ownership of the MMAS; including its conceptual basis, content, structure, and all adaptations remains solely with the Licensor. Nothing in this agreement conveys authorship, joint ownership, or derivative claim to the Licensee. Unauthorized use, adaptation, or representation of the MMAS as public domain content or under a modified identity will result in immediate termination of this license and may lead to legal action.
This agreement shall remain in effect until terminated. The Licensor reserves the right to revoke the license in the event of breach, misuse, or deviation from the terms herein. Upon termination, the Licensee must cease all use of the MMAS and destroy all copies in any format, physical or digital.
The MMAS is provided as-is, without warranty of any kind. The Licensor assumes no liability for how the MMAS is used, interpreted, or relied upon in clinical decision-making, health outcomes, or research findings.
This agreement is governed by the laws of the State of California, United States of America. Any disputes arising under this license shall be resolved in accordance with those laws.
The Licensor reserves the right to revise this EULA at any time. Updated terms will be communicated to registered Licensees or posted publicly at www.adherence.cc. Continued use of the MMAS following notice of such changes constitutes acceptance of the new terms.
This EULA constitutes the entire agreement between the parties regarding the MMAS and supersedes all prior representations or understandings.
By using the MMAS, the Licensee acknowledges that they have read, understood, and agreed to these terms.
Copyright 2023 adherence. - All Rights Reserved. Patient adherence Medication Adherence MMAS® MMAS-4™ MMAS-8™ Morisky Medication Adherence Scale™ Morisky Scale™
health tech, digital health, telehealth, healthcare innovation, medical technology, ehealth, health informatics, remote patient monitoring, mhealth, telemedicine, patient engagement, wearable health devices, health app, ai in healthcare, telehealth solutions, virtual care, health tech startups, connected health, population health management, healthcare analytics, personalized medicine
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.